Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sagres: Sifting wheat from chaff

One of the big issues in target discovery today is the fact that hundreds of genes may be up-regulated in any given disease state. Such is the obstacle in comparing cancerous and healthy tissue. To solve that problem, Sagres Discovery Inc. has taken a 20-year old technology - insertional mutagenesis using a retrovirus to identify causative cancer genes - and made it high throughput.

Sagres' technology has its origins at the University of California at Davis, where

Read the full 773 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers